Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction

Imagem de Miniatura
Arquivos
art_DOURADO_Rosuvastatin_prevents_myocardial_necrosis_in_an_experimental_model_2011.PDF (619.78 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2011
Editora
ASSOC BRAS DIVULG CIENTIFICA
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
GALVAO, T. F. G.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.44, n.5, p.469-476, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Dyslipidemia is related to the progression of atherosclerosis and is an important risk factor for acute coronary syndromes. Our objective was to determine the effect of rosuvastatin on myocardial necrosis in an experimental model of acute myocardial infarction (AMI). Male Wistar rats (8-10 weeks old, 250-350 g) were subjected to definitive occlusion of the left anterior descending coronary artery to cause AMI. Animals were divided into 6 groups of 8 to 11 rats per group: G1, normocholesterolemic diet; G2, normocholesterolemic diet and rosuvastatin (1 mg.kg(-1).day(-1)) 30 days after AMI; G3, normocholesterolemic diet and rosuvastatin (1 mg.kg(-1).day(-1)) 30 days before and after AMI; G4, hypercholesterolemic diet; G5, hypercholesterolemic diet and rosuvastatin (1 mg.kg(-1).day(-1)) 30 days after AMI; G6, hypercholesterolemic diet and rosuvastatin (1 mg.kg(-1).day(-1)) 30 days before and after AMI. Left ventricular function was determined by echocardiography and percent infarct area by histology. Fractional shortening of the left ventricle was normal at baseline and decreased significantly after AMI (P < 0.05 in all groups), being lower in G4 and G5 than in the other groups. No significant difference in fractional shortening was observed between G6 and the groups on the normocholesterolemic diet. Percent infarct area was significantly higher in G4 than in G3. No significant differences were observed in infarct area among the other groups. We conclude that a hypercholesterolemic diet resulted in reduced cardiac function after AMI, which was reversed with rosuvastatin when started 30 days before AMI. A normocholesterolemic diet associated with rosuvastatin before and after AMI prevented myocardial necrosis when compared with the hypercholesterolemic condition.
Palavras-chave
Acute myocardial infarction, Rosuvastatin, Hypercholesterolemia, Myocardial necrosis
URI
https://observatorio.fm.usp.br/handle/OPI/22856
Referências
  1. Aguilar-Salinas CA, 1998, ATHEROSCLEROSIS, V141, P203, DOI 10.1016/S0021-9150(98)00198-1
  2. [Anonymous], 1986, LANCET, V1, P397
  3. Zoccali C, 2003, BLOOD PURIFICAT, V21, P29, DOI 10.1159/000067852
  4. PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403
  5. Strandberg TE, 1999, LANCET, V353, P118, DOI 10.1016/S0140-6736(05)76154-7
  6. KLONER RA, 1983, CIRCULATION, V68, P8
  7. Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
  8. Koh KK, 2000, CARDIOVASC RES, V47, P648, DOI 10.1016/S0008-6363(00)00146-2
  9. Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201
  10. Scalia R, 1998, ARTERIOSCL THROM VAS, V18, P1093
  11. [Anonymous], 1985, CIRCULATION, V71, p849A
  12. Peterson JT, 2000, CARDIOVASC RES, V46, P307, DOI 10.1016/S0008-6363(00)00029-8
  13. BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162
  14. Nissen SE, 2006, JAMA-J AM MED ASSOC, V295, P1556, DOI 10.1001/jama.295.13.jpc60002
  15. Lagrand WK, 1999, CIRCULATION, V100, P96
  16. Boger RH, 2006, ANN MED, V38, P126, DOI 10.1080/07853890500472151
  17. Boger RH, 1998, CIRCULATION, V98, P1842
  18. Davignon J, 1999, CURR OPIN LIPIDOL, V10, P543, DOI 10.1097/00041433-199912000-00010
  19. Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643
  20. CHAGAS ACP, 1989, BRAZ J MED BIOL RES, V22, P1337
  21. DALUZ PL, 1990, BRAZ J MED BIOL RES, V23, P317
  22. de Carvalho Maria Helena C, 2006, Arq Bras Endocrinol Metabol, V50, P304, DOI 10.1590/S0004-27302006000200016
  23. DIAMOND GA, 1978, AM HEART J, V95, P204, DOI 10.1016/0002-8703(78)90464-7
  24. Galvao TFGG, 2006, EUR HEART J, V27, P250
  25. JORIS I, 1983, AM J PATHOL, V113, P341
  26. MEBAZAA A, 1995, AM J PHYSIOL-HEART C, V268, pH250
  27. Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
  28. Scheuren N, 2002, J MOL CELL CARDIOL, V34, P29, DOI 10.1006/jmcc.2001.1484
  29. Terp K, 1999, SCAND CARDIOVASC J, V33, P265
  30. THORGEIRSSON UP, 1994, J NEURO-ONCOL, V18, P89, DOI 10.1007/BF01050415
  31. TIMI: TIMI Study Group, 1985, NEW ENGL J MED, V312, P932
  32. TYAGI SC, 1993, CLIN BIOCHEM, V26, P191, DOI 10.1016/0009-9120(93)90025-2
  33. Yang RZ, 2006, PLOS MED, V3, P884, DOI 10.1371/journal.pmed.0030287

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor